Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others.
DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034
Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France.
Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends.
The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM.
According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor.
Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis
Recent Developments:
In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others.
In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC.
In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary.
In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025.
In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery.
The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA).
The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells.
DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others.
Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights.
Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape.
MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth.
Table of Contents
1. Key Insights
2. Report Introduction
3. Merkel Cell Carcinoma Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Merkel Cell Carcinoma Background and Overview
7. Merkel Cell Carcinoma Epidemiology and Market Methodology
8. Epidemiology and Merkel Cell Carcinoma Patient Population
9. Merkel Cell Carcinoma Patient Journey
10. Merkel Cell Carcinoma Marketed Therapies
11. Merkel Cell Carcinoma Emerging Drug Profiles
12. MCC: Market Analysis
13. Key Opinion Leaders' Views
14. Merkel Cell Carcinoma Unmet Needs
15. Merkel Cell Carcinoma SWOT Analysis
16. Merkel Cell Carcinoma Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Merkel Cell Carcinoma Pipeline Insight
Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
The U.S. is auctioning a seized US$325M Russian yacht with 8 state rooms, a helipad, a gym and a spa
WASHINGTON — The United States is auctioning off the US$325 million yacht Amadea, its first sale of a seized Russian luxury ship since the start of Moscow's invasion of Ukraine. The auction, which closes Sept. 10, comes as U.S. President Donald Trump seeks to increase pressure on Russian President Vladimir Putin to end the war. The U.S. has said it's working with allies to put pressure on Russian oligarchs, some of whom are close to Putin and have had their yachts seized, to try to compel him to stop the war. The 348-foot-long (106-metre-long) yacht, seized three years ago and currently docked in San Diego, was custom built by the German company Lürssen in 2017. Designed by François Zuretti, the yacht features an interior with extensive marble work, eight state rooms, a beauty salon, a spa, a gym, a helipad, a swimming pool and an elevator. It accommodates 16 guests and 36 crew members. Determining the real ownership of the Amadea has been an issue of contention because of an opaque trail of trusts and shell companies. The yacht is registered in the Cayman Islands and is owned by Millemarin Investments Ltd., also based in the Cayman Islands. The U.S. contends that Suleiman Kerimov, an economist and former Russian politician, who was sanctioned by the U.S. in 2018 for alleged money laundering, owns the yacht. Meanwhile, Eduard Khudainatov, a former chairman and chief executive of the state-controlled Russian oil and gas company Rosneft, who has not been sanctioned, claims to own it. U.S. prosecutors say Khudainatov is a straw owner of the yacht, intended to conceal the yacht's true owner, Kerimov. Litigation over the true ownership of the yacht is ongoing. A representative of Khudainatov said in an emailed statement Wednesday that the planned sale of the yacht is 'improper and premature' since Khudainatov is appealing a forfeiture ruling. 'We doubt it will attract any rational buyer at fair market price, because ownership can, and will, be challenged in courts outside the United States, exposing purchasers to years of costly, uncertain litigation,' said the representative, Adam Ford. The yacht has been virtually untouched since the National Maritime Services took custody of it in 2022. To submit a sealed bid on it, bidders must put in a 10 million euro deposit, the equivalent of roughly $11.6 million, to be considered. Ford said Khudainatov would go after any proceeds from the sale of the yacht, estimated to be worth $325 million. 'Should the government press ahead simply to staunch the mounting costs it is imposing on the American taxpayer, we will pursue the sale proceeds, and any shortfall from fair market value, once we prevail in court,' Ford said. A U.S. aid package for Ukraine signed into law in May 2024 gave the U.S. the ability to seize Russian state assets located in the U.S. and use them for the benefit of Kyiv, which was attacked by Russia in February 2022. Fatima Hussein, The Associated Press
Toronto Sun
3 hours ago
- Toronto Sun
Carney meeting with cabinet, premiers to discuss latest U.S. tariffs
Published Aug 06, 2025 • 2 minute read Prime Minister Mark Carney meets with all of Canada's premiers during the First Ministers' Meeting at TCU Place. Photo taken in Saskatoon, Sask. on Monday, June 2, 2025. Photo by Michelle Berg / Postmedia OTTAWA — Prime Minister Mark Carney is holding virtual meetings with his cabinet and the premiers today, less than a week after U.S. President Donald Trump hit Canada with a baseline 35 per cent tariff. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account This latest trade war escalation applies only to goods not covered by the Canada-United States-Mexico agreement on free trade, better known as CUSMA. The latest levy took effect on Friday after the two countries failed to hit an Aug. 1 deadline to secure a new trade agreement. Ontario Premier Doug Ford said Wednesday he had a 'good conversation' with U.S. Commerce Secretary Howard Lutnick on Tuesday that was 'positive.' He also said he was frustrated by the impacts of high U.S. tariffs on his province's economy. Ford warned Trump's 'decision to increase tariffs on Canadian goods to 35 per cent is only adding to the uncertainty for businesses and workers.' 'You can't have tariffs on one side and not the other. I still stand by what I say — dollar for dollar, tariff for tariff. They understand strength, not weakness, and we should never, ever roll over and be weak,' Ford told reporters at a news conference Wednesday in Thornhill, Ont. This advertisement has not loaded yet, but your article continues below. Ford said he wants to see more done to stimulate the economy. He called on Ottawa to cut taxes and said the Bank of Canada should drop its interest rate. 'We have to get the governor of the Bank of Canada to lower those damn interest rates from 2.75,' he said. 'Knock 'em down. Build confidence. 'Let's work together on getting rid of the HST on homebuyers, and not just first (time) ones. Let's stimulate the market and we'll follow suit if the federal government does that.' Ford said he believes the 'prime minister is doing everything in his power to get a fair trade deal with the U.S.' Carney told a press conference in B.C. on Tuesday that he has not talked to Trump in recent days, but will speak with him 'when it makes sense.' The prime minister added that about 85 per cent of trade with the U.S. remains tariff-free because of CUSMA. Sector-specific tariffs, like the 50 per cent duty on steel, aluminum and copper, remain in place. Foreign Affairs Minister Anita Anand and Finance Minister Francois-Philippe Champagne were in Mexico City on Wednesday for meetings with Mexican officials and businesses on trade. — With files from Allison Jones in Thornhill, Ont. Television Basketball Toronto & GTA Columnists Toronto & GTA
Globe and Mail
5 hours ago
- Globe and Mail
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of $5.26 per share. Earnings rose 21% year over year as higher revenues were partially offset by higher operating costs. Total revenues of $9.2 billion also beat the Zacks Consensus Estimate of $8.9 billion. Total revenues rose 9% year over year. Total product revenues increased 9% from the year-ago quarter to $8.77 billion as volume growth was partially offset by continued price declines. Volumes rose 13% in the quarter, backed by strong demand trends for Amgen's drugs globally. Other revenues were $408 million in the quarter, up 17.6% year over year. Performance of AMGN's Key Drugs Evenity recorded sales of $518 million in the quarter, up 32% year over year, driven by solid volume growth in the United States. Evenity sales beat the Zacks Consensus Estimate of $478.0 million as well as our model estimate of $461.8 million. Repatha generated revenues of $696.0 million, up 31% year over year, driven by higher volume growth, which was partially offset by lower prices and unfavorable changes to estimated sales deductions. Repatha sales beat the Zacks Consensus Estimate of $672.0 million and our model estimate of $663.8 million. Prolia revenues came in at $1.12 billion, down 4% from the year-ago quarter due to lower pricing. Prolia sales were in line with the Zacks Consensus Estimate but slightly beat our model estimate of $1.01 billion. Xgeva delivered revenues of $532 million, down 5% year over year due to unfavorable changes to estimated sales deductions and volume decline. Xgeva sales beat the Zacks Consensus Estimate of $508.0 million as well as our model estimate of $506.4 million. Patents for RANKL antibodies (including sequences) for Prolia and Xgeva expired in February 2025 in the United States, while the same will expire in some European countries in November 2025. Sales of these best-selling drugs are expected to erode significantly from the second half of 2025 as three biosimilars have been launched in the U.S. market. Sales of Otezla were $618.0 million in the quarter, up 14% year over year driven by volume growth and favorable changes to estimated sales deductions. Otezla sales beat the Zacks Consensus Estimate of $535.0 million as well as our estimate of $504.1 million. Asthma drug Tezspire (tezepelumab) recorded sales of $342.0 million in the quarter, up 46% year over year, driven by volume growth. Tezspire sales beat the Zacks Consensus Estimate of $326.0 million as well as our estimate of $250.7 million. Amgen has a partnership with AstraZeneca AZN for Tezspire. Amgen and AstraZeneca share costs and profits equally after AstraZeneca pays a mid-single-digit inventor royalty to Amgen. While AstraZeneca leads development, Amgen leads manufacturing. Tepezza sales rose 5% year over year to $505 million due to higher inventory levels. New cancer drug Imdelltra (tarlatamab) recorded sales of $134 million in the second quarter compared with $81 million in the previous quarter. The drug's 65% sequential growth was driven by volume growth. In the second quarter, biosimilar portfolio sales grew 40% year over year to $661 million. AMGN's Cost and Margin Discussion Adjusted operating margin rose 0.7 percentage points to 48.9% in the quarter. Adjusted operating expenses increased 8% to $4.89 billion. R&D expenses rose 18% year over year to $1.42 billion, reflecting continued investment in the late-stage pipeline. SG&A declined 2% to $1.65 billion. AMGN Tweaks 2025 Guidance Amgen slightly raised its revenue and earnings outlook for 2025. Total revenues are expected in the range of $35.0 billion to $36.0 billion, slightly more than the prior expectation of $34.3 billion to $35.7 billion. Adjusted earnings per share are expected in the range of $20.20 to $21.30 versus the prior expectation of $20.00 to $21.20 per share. The guidance includes the impact from tariffs implemented to date but does not reflect any impact from potential tariffs on pharmaceutical imports. Adjusted operating margin is expected to be roughly 45%, down from the prior expectation of approximately 46%. The operating margin range was lowered to account for incremental R&D costs and launch and commercial investments. Adjusted R&D expense is expected to grow more than 20% compared to the prior expectation of approximately 20% in 2025. The adjusted tax rate was maintained in the range of 14.5% to 16.0%. Capital expenditures are expected to be approximately $2.3 billion. Amgen expects to buy back shares worth not more than $500 million in 2025. Update on AMGN's Diabetes/Obesity Pipeline Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and maybe less frequent dosing. This key feature differentiates it from Eli Lilly LLY and Novo Nordisk 's NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy. LLY's Zepbound and NVO's Wegovy are weekly injections. In clinical studies, MariTide has shown strong efficacy with up to approximately 20% weight loss at 52 weeks without a plateau and with a clinically meaningful improvement in cardiometabolic parameters, including hemoglobin A1c. In March, Amgen initiated two phase III studies on MariTide in obesity as part of its comprehensive MARITIME phase III program. Separate phase III studies on MariTide in obesity, with or without type II diabetes, are currently enrolling patients. Since June, Amgen has initiated two more phase III studies. The first, MARITIME-CV, will evaluate cardiovascular outcomes in obese adults living with atherosclerotic cardiovascular disease, while the second, MARITIME-HF, will evaluate the reduction of heart failure events and cardiovascular risk in adults living with heart failure with a preserved or mildly reduced ejection fraction and obesity. Amgen is also planning to initiate another phase III study for obstructive sleep apnea in the second half. Separate phase II studies on obesity and type II diabetes are also ongoing, with data readouts expected in the fourth quarter. Our Take on AMGN's Q2 Results Amgen's second-quarter results were strong as it beat estimates for both earnings and sales. Sales of most of its key products, Repatha, Blincyto, Xgeva, Evenity and Otezla beat estimates. Fifteen products, including Repatha, Blincyto, Tezspire, Uplizna, Tavneos and Evenity, achieved double-digit volume growth in the quarter. New biosimilar products are also contributing to sales growth. Amgen slightly raised its financial outlook for 2025. However, despite the strong quarterly performance, Amgen's shares declined slightly in after-hours trading on Tuesday. Year to date, Amgen's stock has risen 17.1% compared with the industry 's 3.2% increase. Image Source: Zacks Investment Research Amgen's key medicines like Evenity, Repatha and Blincyto, as well as newer medicines like Tavneos and Tezspire, are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products like Enbrel. New biosimilar launches are also contributing to top-line growth. However, increased pricing headwinds and competitive pressure are hurting sales of many products. Weakness in some key brands like Enbrel and Lumakras create potential revenue headwinds. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline from the second half of 2025 due to biosimilar competition. Investors are keeping an eye on Amgen's progress with its obesity candidate, MariTide. AMGN's Zacks Rank Amgen currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report
